Fluticasone propionate is under clinical development by Ellodi Pharmaceuticals and currently in Phase III for Eosinophilic Esophagitis. According to GlobalData, Phase III drugs for Eosinophilic Esophagitis have a 40% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Fluticasone propionate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Fluticasone propionate overview

Fluticasone propionate (APT-1011) is under development for the treatment of eosinophilic esophagitis. It is administered as orally disintegrating tablet. It acts by targeting the glucocorticoid receptor. The drug candidate is developed based on advatab ODT technology.

For a complete picture of Fluticasone propionate’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.